A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria.
Patients (n = 56) with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 and 4 mg) versus 60 mg terfenadine and placebo administered three times daily. All three active preparations were found to be effective, and significantly better than placebo, in controlling the signs and symptoms of urticaria. No significant differences were found between the active preparations, although in some cases efficacy trends favoured 8 mg acrivastine and terfenadine over 4 mg acrivastine. No significant differences were noted between the active treatments and placebo with regard to reports of drowsiness.
van Joost
T
T
Department of Dermatology and Venereology, Erasmus University Rotterdam, The Netherlands.
Blog
F B
FB
Westerhof
W
W
Jansen
F C
FC
Starink
T M
TM
den Boer
M S
MS
Kuneman
J J
JJ
Harvey
S G
SG
Gibson
J R
JR
D000328:Adult; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D016593:Terfenadine; D014311:Triprolidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014581:Urticaria / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D010919:Placebos; D011725:Pyridines; D014311:Triprolidine; D016593:Terfenadine; C043648:acrivastine